[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU2001134170A - NEISSERIA Antigenic Peptides - Google Patents

NEISSERIA Antigenic Peptides

Info

Publication number
RU2001134170A
RU2001134170A RU2001134170/13A RU2001134170A RU2001134170A RU 2001134170 A RU2001134170 A RU 2001134170A RU 2001134170/13 A RU2001134170/13 A RU 2001134170/13A RU 2001134170 A RU2001134170 A RU 2001134170A RU 2001134170 A RU2001134170 A RU 2001134170A
Authority
RU
Russia
Prior art keywords
fragment
protein
neisseria
composition
polypeptide
Prior art date
Application number
RU2001134170/13A
Other languages
Russian (ru)
Other versions
RU2284332C2 (en
Inventor
Вега Масиньяни
Винченцо СКАРЛАТО
Мария СКАРСЕЛЛИ
Чесира ГАЛЕОТТИ
Мария Роса МОРА
Original Assignee
Чирон С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911683.2A external-priority patent/GB9911683D0/en
Application filed by Чирон С.П.А. filed Critical Чирон С.П.А.
Publication of RU2001134170A publication Critical patent/RU2001134170A/en
Application granted granted Critical
Publication of RU2284332C2 publication Critical patent/RU2284332C2/en

Links

Claims (13)

1. Фрагмент белка, описанный в W099/24578, где указанный фрагмент содержит, по крайней мере, одну антигенную детерминанту.1. The protein fragment described in W099 / 24578, where the specified fragment contains at least one antigenic determinant. 2. Фрагмент по п.1, имеющий длину в 100 аминокислот или менее.2. The fragment according to claim 1, having a length of 100 amino acids or less. 3. Фрагмент по п.1 или 2, имеющий длину в 3 аминокислоты или более.3. The fragment according to claim 1 or 2, having a length of 3 amino acids or more. 4. Фрагмент по любому из предшествующих пунктов, представляющий собой один из 14151 фрагмента, представленных в таблице I.4. A fragment according to any one of the preceding paragraphs, which is one of the 14151 fragments shown in table I. 5. Полипептид, имеющий 50%-ную или более идентичность с фрагментом по любому из предшествующих пунктов.5. A polypeptide having 50% or more identity with a fragment according to any one of the preceding paragraphs. 6. Белок, содержащий один или более фрагментов по пп.1, 2 или 3, при условии, что указанный белок не является одной из 446 полноразмерных последовательностей белка, описанных в W099/245786. A protein containing one or more fragments according to claims 1, 2 or 3, provided that the protein is not one of the 446 full-sized protein sequences described in W099 / 24578 7. Антитело, распознающее фрагмент по любому из пп.1-4.7. An antibody that recognizes a fragment according to any one of claims 1 to 4. 8. Белок, содержащий пептидную последовательность, где указанная пептидная последовательность распознается антителом по п.7.8. A protein containing a peptide sequence, where the specified peptide sequence is recognized by the antibody according to claim 7. 9. Нуклеиновая кислота, кодирующая фрагмент по пп.1, 2 или 3, полипептид по п.5 или белок по п.8.9. A nucleic acid encoding a fragment of claims 1, 2 or 3, a polypeptide of claim 5, or a protein of claim 8. 10. Композиция, содержащая фрагмент по пп.1, 2 или 3, полипептид по п.5, белок по п.8, антитело по п.7 и/или нуклеиновую кислоту по п.9, где указанной композицией является вакцина, диагностический реагент или иммуногенная композиция.10. A composition comprising a fragment according to claims 1, 2 or 3, a polypeptide according to claim 5, a protein according to claim 8, an antibody according to claim 7 and / or a nucleic acid according to claim 9, wherein said composition is a vaccine, a diagnostic reagent or immunogenic composition. 11. Композиция по п.10 для использования в качестве лекарственного средства.11. The composition of claim 10 for use as a medicine. 12. Применение фрагмента по пп.1, 2 или 3, полипептида по п.5, белка по п.8, антитела по п.7, и/или нуклеиновой кислоты по п.9 для изготовления (i) лекарственного средства для лечения или профилактики инфекции, вызываемой бактериями Neisseria; (ii) диагностического реагента для обнаружения присутствия бактерии Neisseria или антител, вырабатываемых против бактерии Neisseria; и/или (iii) реагента, который может способствовать продуцированию антител против бактерии Neisseria.12. The use of a fragment according to claims 1, 2 or 3, a polypeptide according to claim 5, a protein according to claim 8, an antibody according to claim 7, and / or a nucleic acid according to claim 9 for the manufacture of (i) a medicament for treatment or prevention of infection caused by Neisseria bacteria; (ii) a diagnostic reagent for detecting the presence of the Neisseria bacterium or antibodies produced against the Neisseria bacterium; and / or (iii) a reagent that can facilitate the production of antibodies against the bacterium Neisseria. 13. Способ лечения пациента, включающий введение указанному пациенту терапевтически эффективного количества композиции по п.10.13. A method of treating a patient, comprising administering to said patient a therapeutically effective amount of a composition of claim 10.
RU2001134170/13A 1999-05-19 2000-05-19 Neisseria antigenic peptides RU2284332C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9911683.2 1999-05-19
GBGB9911683.2A GB9911683D0 (en) 1999-05-19 1999-05-19 Antigenic peptides

Publications (2)

Publication Number Publication Date
RU2001134170A true RU2001134170A (en) 2003-07-27
RU2284332C2 RU2284332C2 (en) 2006-09-27

Family

ID=10853774

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001134170/13A RU2284332C2 (en) 1999-05-19 2000-05-19 Neisseria antigenic peptides

Country Status (18)

Country Link
US (1) US20070053926A1 (en)
EP (3) EP1767641A1 (en)
JP (2) JP2003500040A (en)
CN (2) CN101397336A (en)
AT (1) ATE366313T1 (en)
AU (2) AU775972B2 (en)
BR (1) BR0010720A (en)
CA (1) CA2374550A1 (en)
CY (1) CY1106875T1 (en)
DE (1) DE60035419T2 (en)
DK (1) DK1194560T3 (en)
ES (1) ES2288477T3 (en)
GB (1) GB9911683D0 (en)
MX (1) MXPA01011833A (en)
NZ (1) NZ515936A (en)
PT (1) PT1194560E (en)
RU (1) RU2284332C2 (en)
WO (1) WO2000071574A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500738A (en) 1996-09-17 2001-01-23 カイロン コーポレイション Compositions and methods for treating intracellular diseases
BR0010130A (en) 1999-04-30 2002-06-04 Chiron Spa Preserved neisseria antigens
CN102580072A (en) 1999-05-19 2012-07-18 诺华疫苗和诊断有限公司 Combination neisserial compositions
PT1947187E (en) 2000-02-28 2011-07-04 Novartis Vaccines & Diagnostic Hybrid expression of neisserial proteins
US7094882B2 (en) 2000-04-21 2006-08-22 Yeda Research And Development Co. Ltd. Growth factor which acts through erb b-4 rtk
ATE469915T1 (en) 2001-07-27 2010-06-15 Novartis Vaccines & Diagnostic ANTIBODIES AGAINST MENINGOCOCC ADHESIN APP
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
EP2258386A3 (en) * 2002-08-02 2011-11-02 GlaxoSmithKline Biologicals S.A. Neisseria Vaccine composition
NZ562998A (en) 2002-10-11 2008-05-30 Novartis Vaccines & Diagnostic Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
EP2360258B1 (en) 2005-02-18 2014-10-08 Angiochem Inc. Aprotinin polypeptides for transporting a compound across the blood-brain barrier
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
AU2009304560A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of GLP-1 agonists and uses thereof
MX2011005963A (en) 2008-12-05 2011-09-01 Angiochem Inc Conjugates of neurotensin or neurotensin analogs and uses thereof.
CA2759129C (en) 2009-04-20 2018-12-11 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
AU2010268726A1 (en) 2009-07-02 2012-01-19 Angiochem Inc. Multimeric peptide conjugates and uses thereof
KR101061017B1 (en) * 2009-10-23 2011-08-31 (주) 수파드엘릭사 Pharmaceutical composition for inhibiting growth and / or metastasis of cancer cells
CA2803646A1 (en) * 2010-07-02 2012-01-05 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
PL3246044T5 (en) 2010-08-23 2024-06-17 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
ES2728282T3 (en) 2010-09-10 2019-10-23 Wyeth Llc Non-lipidated variants of ORF2086 antigens from Neisseria meningitidis
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
RU2665841C2 (en) 2012-03-09 2018-09-04 Пфайзер Инк. Neisseria meningitidis compositions and methods of use thereof
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (en) 2013-09-08 2018-07-31 Пфайзер Инк. Immunogenic composition for neisseria meningitidis (options)
RU2723045C2 (en) 2015-02-19 2020-06-08 Пфайзер Инк. Compositions of neisseria meningitidis and methods for preparation thereof
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
PE20191107A1 (en) 2017-01-31 2019-08-26 Pfizer COMPOSITIONS OF NEISSERIA MENINGITIDIS AND RESPECTIVE METHODS

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2386796A (en) 1942-08-05 1945-10-16 Bond Crown & Cork Co Extruding device
DE2855719A1 (en) 1978-12-22 1980-07-10 Siemens Ag DENTAL HANDPIECE ARRANGEMENT
US4336336A (en) 1979-01-12 1982-06-22 President And Fellows Of Harvard College Fused gene and method of making and using same
AU545912B2 (en) 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
DK188582A (en) 1981-04-29 1982-10-30 Biogen Nv BACILLUS CLONING VECTORS RECOMBINATION DNA MOLECULES BACILLUS VALUES TRANSFORMED THEREOF, AND PROCEDURES FOR EXPRESSION OF PROCESSED DNA SEQUENCES AND PREPARATION OF POLYPEPTIDES CODED THEREOF
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
CA1341116C (en) 1983-02-22 2000-10-17 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis or foreign protein
JPS59166086A (en) 1983-03-09 1984-09-19 Teruhiko Beppu Novel development type plasmid and development of vitular prochymosin gene in escherichia coli using it
US4546083A (en) 1983-04-22 1985-10-08 Stolle Research & Development Corporation Method and device for cell culture growth
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
JPS59205983A (en) 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン Development of different kind gene by procaryotic microorganism
US4663280A (en) 1983-05-19 1987-05-05 Public Health Research Institute Of The City Of New York Expression and secretion vectors and method of constructing vectors
DE3485810T2 (en) 1983-05-27 1992-12-10 Texas A & M University Syst METHOD FOR PRODUCING A RECOMBINANT BACULOVIRUS EXPRESSION VECTOR.
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
JPS6054685A (en) 1983-09-02 1985-03-29 Suntory Ltd Improved manifestation vector and its use
EP0136907A3 (en) 1983-10-03 1986-12-30 Genentech, Inc. A xenogeneic expression control system, a method of using it, expression vectors containing it, cells transformed thereby and heterologous proteins produced therefrom
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
EP0164556B1 (en) 1984-05-11 1994-03-02 Chiron Corporation Enhanced yeast transcription employing hybrid promoter region constructs
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4745056A (en) 1984-10-23 1988-05-17 Biotechnica International, Inc. Streptomyces secretion vector
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
EP0196056B1 (en) 1985-03-28 1991-05-22 Chiron Corporation Improved expression using fused genes providing for protein product
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4865974A (en) 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
JPS6296086A (en) 1985-10-21 1987-05-02 Agency Of Ind Science & Technol Composite plasmid
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
ATE110111T1 (en) 1986-05-02 1994-09-15 Gist Brocades Nv SECRETION SIGNAL SELECTION VECTORS FOR EXTRACELLULAR PROTEIN SYNTHESIS IN BACILLA.
JP2612874B2 (en) 1986-10-02 1997-05-21 マサチユセツツ・インスチチユート・オブ・テクノロジー Methods of regulating protein metabolic stability
JPS63123383A (en) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp Hybrid promoter, manifestation regulating dna sequence and manifestation vector
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
DK175243B1 (en) 1987-03-23 2004-07-19 Zymogenetics Inc Expression vector capable of directing expression of heterologous genes or cDNA in yeast, yeast host cell and method for increased production of proteins in yeast host cells
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
DK463887D0 (en) 1987-09-07 1987-09-07 Novo Industri As GAERLEADER
ATE117375T1 (en) 1987-09-11 1995-02-15 Whitehead Biomedical Inst TRANSDUCTION ALTERED FIBROBLASS AND THEIR APPLICATION.
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
CN1074422C (en) 1987-11-18 2001-11-07 希龙股份有限公司 Nanbv diagnostics and vaccines
WO1989005349A1 (en) 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US4973551A (en) 1988-01-15 1990-11-27 Merck & Co., Inc. Vector for the expression of fusion proteins and protein immunogens
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
WO1989009271A1 (en) 1988-03-21 1989-10-05 Viagene, Inc. Recombinant retroviruses
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
EP0454781B1 (en) 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
WO1990009441A1 (en) 1989-02-01 1990-08-23 The General Hospital Corporation Herpes simplex virus type i expression vector
JP3140757B2 (en) 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート Packaging defective HIV provirus, cell lines and uses thereof
WO1990011361A1 (en) 1989-03-17 1990-10-04 E.I. Du Pont De Nemours And Company External regulation of gene expression
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE277193T1 (en) 1989-03-21 2004-10-15 Vical Inc EXPRESSION OF EXOGENEOUS POLYNUCLEOTIDE SEQUENCES IN VERTEBRATES
JPH0832638B2 (en) 1989-05-25 1996-03-29 カイロン コーポレイション Adjuvant formulation comprising submicron oil droplet emulsion
NL9021328A (en) 1989-08-15 1992-06-01 Pasminco Australia Ltd Zinc vapour absorption in molten lead - using a cyclone contact and sepn. stage with reduced plant size
WO1991002805A2 (en) 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
WO1992005266A2 (en) 1990-09-21 1992-04-02 Viagene, Inc. Packaging cells
WO1992007945A1 (en) 1990-10-30 1992-05-14 Dana Farber Cancer Institute Cell type specific alteration of levels of gene products in neural cells
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
SE9003978D0 (en) 1990-12-13 1990-12-13 Henrik Garoff DNA EXPRESSION SYSTEM BASED ON A VIRUS REPLICATION
ATE190354T1 (en) 1990-12-20 2000-03-15 Arch Dev Corp The University O CONTROL OF GENE EXPRESSION BY IONIZING RADIATION
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
FR2681786A1 (en) 1991-09-27 1993-04-02 Centre Nat Rech Scient RECOMBINANT VECTORS OF VIRAL ORIGIN, PROCESS FOR OBTAINING SAME AND THEIR USE FOR THE EXPRESSION OF POLYPEPTIDES IN MUSCLE CELLS.
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US6100380A (en) * 1991-10-28 2000-08-08 Cytran, Inc. Immunomodulating peptides and methods of use
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
CA2128616A1 (en) 1992-01-23 1993-08-05 Gary H. Rhodes Ex vivo gene transfer
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California Methods and compositions for targeting specific tissue.
JPH09507741A (en) 1992-06-10 1997-08-12 アメリカ合衆国 Vector particles resistant to inactivation by human serum
ATE344333T1 (en) * 1992-07-07 2006-11-15 Fuso Pharmaceutical Ind PROBE FOR DIAGNOSING AN INFECTIOUS DISEASE CAUSED BY ENTEROCOCCUS FAECALIS
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
ES2312164T3 (en) 1992-09-25 2009-02-16 Aventis Pharma S.A. ADENOVIRUS VECTORS FOR THE TRANSFER OF STRANGE GENES IN CELLS OF THE CENTRAL NERVOUS SYSTEM, PARTICULARLY IN THE BRAIN.
DE69333886T2 (en) 1992-11-18 2006-07-27 Arch Development Corp., Chicago Adenovirus-guided gene transfer to the heart and smooth vascular muscle
CA2145641C (en) 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
ATE174929T1 (en) * 1993-01-23 1999-01-15 Inmunologia & Genetica Aplic SYNTHETIC PEPTIDES AND VACCINES AGAINST PARVOVIRUS
US5348358A (en) 1993-02-22 1994-09-20 Selick David A Contact lens insertion tool
DE4311651A1 (en) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus for the transport of foreign DNA into higher eukaryotic cells
WO1994023697A1 (en) 1993-04-22 1994-10-27 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
WO1994028157A1 (en) 1993-05-26 1994-12-08 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Fusion proteins containing adeno-associated virus rep protein and bacterial protein
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
SK282843B6 (en) 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defective adenovirus vectors and use thereof in gene therapy
CA2167706A1 (en) 1993-07-27 1995-02-09 Nigel Fraser Modified dna virus vectors and uses therefor
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
ATE215989T1 (en) 1993-09-15 2002-04-15 Chiron Corp RECOMBINANT ALPHAVIRUS VECTOR
FR2710536B1 (en) 1993-09-29 1995-12-22 Transgene Sa Anti-cancer use of a viral vector comprising a gene which modulates the immune and / or inflammatory response.
JPH09505561A (en) 1993-10-01 1997-06-03 アメリカ合衆国 Nervous system gene therapy
ATE437232T1 (en) 1993-10-25 2009-08-15 Canji Inc RECOMBINANT ADENOVIRUS VECTOR AND METHOD OF USE
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
RU2160093C2 (en) 1993-11-16 2000-12-10 Скайефарма Инк. Vesicles with controlled active ingredient release
FR2712603B1 (en) 1993-11-18 1996-02-09 Centre Nat Rech Scient Recombinant viruses, preparation and use in gene therapy.
JPH07241786A (en) 1994-03-08 1995-09-19 Fanuc Ltd Control device for industrial robot
US6780406B1 (en) 1994-03-21 2004-08-24 The Regents Of The University Of Michigan Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
JPH10507061A (en) 1994-04-28 1998-07-14 ザ ユニバーシティ オブ ミシガン Gene delivery vector and packaging cell line using plasmid DNA packaged in adenovirus
CA2158977A1 (en) 1994-05-09 1995-11-10 James G. Respess Retroviral vectors having a reduced recombination rate
JP3816518B2 (en) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド Complementary adenoviral vector systems and cell lines
FR2723588B1 (en) 1994-08-12 1996-09-20 Rhone Poulenc Rorer Sa ADENOVIRUS COMPRISING A GENE ENCODING GLUTATHIONE PEROXYDASE
US6245337B1 (en) * 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
US6121037A (en) * 1994-10-18 2000-09-19 Stojiljkovic; Igor Bacterial hemoglobin receptor genes
IL117483A (en) * 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
AU5741996A (en) 1995-05-22 1996-12-11 Chiron Corporation Position-specific integration of vector constructs into eukaryotic genomes mediated by a chimeric integrase protein
US6083499A (en) * 1996-04-19 2000-07-04 Mycogen Corporation Pesticidal toxins
WO1998006437A2 (en) 1996-08-13 1998-02-19 Chiron Corporation Compositions and methods for polynucleotide delivery
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6583275B1 (en) * 1997-07-02 2003-06-24 Genome Therapeutics Corporation Nucleic acid sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics
US6914131B1 (en) * 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
CA2671261A1 (en) * 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
US6150502A (en) * 1998-04-29 2000-11-21 Genesis Research & Development Corporation Limited Polypeptides expressed in skin cells
BR9910089A (en) * 1998-05-01 2004-06-08 Chiron Corp Compositions and antigens of neisseria meningitidis
PT1947187E (en) * 2000-02-28 2011-07-04 Novartis Vaccines & Diagnostic Hybrid expression of neisserial proteins
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins

Similar Documents

Publication Publication Date Title
RU2001134170A (en) NEISSERIA Antigenic Peptides
RU2002113920A (en) ANTIGENIC PEPTIDES NEISSERIA
RU2002103604A (en) Antigenic Meningococcal Peptides
JP2003500040A5 (en)
RU2221045C2 (en) Haemophilus influenzae antigen omp26, nucleic acid encoding it and its using
RU2004121149A (en) IMMUNIZATION AGAINST CHLAMYDIA TRACHOMATIS
RU2009102815A (en) POLYPEPTIDES FROM NEISSERIA MENINGITIDIS
RU2002117308A (en) 85 kDA ANTIGEN NEISSERIA
GB9224584D0 (en) Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
RU2006101149A (en) RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR FOR TREATMENT OF ALZHEIMER'S DISEASE
US20100280229A1 (en) Polypeptide
JP2003504062A5 (en)
CN1610697A (en) Hepatitis E virus monoclonal antibody or binding active fragment thereof and application thereof
JP5661744B2 (en) Polypeptides from enterococci and their use for vaccination
FI120149B (en) Purified P5 protein of non-typable Haemophilus influenzae as vaccine against a non-typable Haemophilus influenzae strain
Cunningham et al. Immunochemical properties of streptococcal M protein purified by isoelectric focusing
JP2003000270A5 (en)
RU2011116286A (en) MULTI-COMPONENT IMMUNOGENIC COMPOSITION FOR PREVENTING DISEASES CAUSED BY BETA-HEMOLYTIC STREPTOCOCCI (GBS)
KR920004422A (en) Major Neutralizing Determinants of HIV
JPS59501866A (en) Polypeptides useful for vaccination against enteric viruses
US4695562A (en) Synthetic peptide compounds
CN102488898B (en) Carious tooth vaccine and preparation method
RU2007106900A (en) IMMUNOGENIC COMPLEXES, METHOD FOR THEIR PREPARATION AND THEIR APPLICATION IN PHARMACEUTICAL COMPOSITIONS
RU2003107837A (en) GENES AND PROTEINS AND THEIR APPLICATIONS
AU2003299131B2 (en) Therapeutic USPA1-derived peptides